Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 712 across all filing types
Latest filing 2026-05-28 Earnings Release
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Please refer to the attachment.
Earnings Release Classification · 84% confidence The document is a Board Meeting outcome filed under SEBI Listing Regulations reporting the approval of audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, along with the Auditor’s report and details on dividend recommendation and cost auditor appointment. This is an initial public announcement of periodic financial results and attached audited statements rather than a full 10-K or interim narrative report. It fits the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). FY 2026
2026-05-28 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a slide-style presentation titled “Investor Presentation” and “Result Update Presentation Q4 & FY26,” filed under Regulation 30 of SEBI. It contains financial highlights, outlook, strategy slides, and management commentary typical of investor presentations rather than an earnings release (ER) alone or a full annual/interim report. It is distributed as a deck to investors. Therefore, it is classified as an Investor Presentation (IP).
2026-05-28 English
Please refer to the Investor Presentation of the Company for the quarter ended 31.03.2026
Investor Presentation Classification · 92% confidence The document is headed “Investor Presentation” under Regulation 30 of SEBI LODR, includes slides with a business overview, Q4 & FY26 result update, consolidated financial highlights, management commentary, strategy slides, tables and charts. This matches the definition of an Investor Presentation (IP), not just an announcement or brief factsheet.
2026-05-28 English
1. Approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 together with the Report issued by the Statutory Auditors, M/s. Krishaan ....
Interim / Quarterly Report Classification · 85% confidence The document is a board meeting outcome submitted under SEBI LODR Regulation 30, announcing the Board’s approval of the audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, including the full audited statements and auditor’s report. It is not merely a highlights‐only earnings release, nor is it a full annual report or proxy; rather it is a comprehensive financial report for an interim period (quarter ended) with substantive data, fitting the definition of an Interim/Quarterly Report. FY 2026
2026-05-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 88% confidence The document is an Official Stock Exchange filing under SEBI Regulation 30 disclosing audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the Statutory Auditor’s report and detailed line-by-line financial statements. It is not merely a brief earnings highlight (so not ER), nor is it a full Annual Report (10-K), but rather a comprehensive periodic financial report containing substantive financial data. Therefore it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-28 English
Themis Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Regulatory Filings Classification · 85% confidence The document is an intimation under SEBI Listing Regulations about the date of a Board meeting to consider financial results and dividend recommendation. It does not itself contain financial results or attach a report, nor announce management changes. It is a regulatory announcement to the stock exchanges, fitting the general regulatory filings category.
2026-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.